
Capricor Therapeutics (CAPR) Stock Forecast & Price Target
Capricor Therapeutics (CAPR) Analyst Ratings
Bulls say
Capricor Therapeutics is attractive because its lead asset, deramiocel, targets Duchenne muscular dystrophy with a differentiated cell-therapy approach and is already in Phase 3 development, giving the story tangible late-stage clinical and regulatory optionality. The FDA’s acceptance of a major BLA amendment, the extension of the PDUFA date to November 22nd, and the inclusion of 24-month HOPE-3 OLE data support a credible path to approval, while published HOPE-3 results showed a 1.2-point PUL2.0 advantage and about 54% slowing of upper-limb functional loss. Financially, the company ended 2Q:26 with $238 million in cash and reported 3Q26 net loss of $42.7 million, but that balance sheet and manageable burn help fund execution into the key regulatory window.
Bears say
Capricor Therapeutics is a highly speculative biotech with an uncertain regulatory path, as deramiocel already received a CRL in July 2025 for insufficient evidence of effectiveness and the July 2026 AdCom voted 9-3 against effectiveness for DMD cardiomyopathy. The company’s evidence base still rests on a small Phase II dataset supplemented by open-label follow-up, an external comparator, and topline Phase HOPE-3 data, which may not satisfy the FDA, while the proposed upper limb indication and November 22 review add more uncertainty. Commercially and financially, launch depends on outsourced execution, payer acceptance, and quarterly infusion logistics, and a delay could jeopardize the expected near-term non-dilutive cash infusion of >$230M and force dilution or litigation-driven disruptions.
This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Capricor Therapeutics (CAPR) Forecast
Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares